Non-alcoholic Steatohepatitis Biomarkers Market Size & Growth Forecast 2026–2035, By Segments (Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Non-alcoholic Steatohepatitis Biomarkers Market size was more than USD 1.71 Billion in 2025 and is set to grow at a 22.9% CAGR between 2026 and 2035, crossing USD 13.44 Billion by 2035. The industry revenue for 2026 is assessed at USD 2.06 billion.

• Base Year Value (2025): USD 1.71 Billion
• CAGR (2026-2035): 22.9%
• Forecast Year Value (2035): USD 13.44 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Non-alcoholic Steatohepatitis Biomarkers Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for 56.60% of the market in 2025, supported by advanced diagnostic infrastructure, strong biomarker validation efforts, and broad integration into clinical research and specialist care.
  • Asia Pacific is forecast to grow at a 25.19% CAGR as healthcare access expands, liver disease awareness improves, and demand rises for biomarker-based testing in clinical and research settings.

• Segment Momentum:

  • Serum Biomarkers captured 33.07% of the market in 2025 because blood-based testing supports routine monitoring, large-scale patient evaluation, and practical use across clinical and research settings.
  • Diagnostic Labs are the fastest-growing end users as biomarker testing increasingly shifts toward scalable clinical evaluation and routine patient identification and follow-up.

• Market Expansion Drivers:

  • Rising NASH prevalence driving demand for early non-invasive diagnostic biomarkers.
  • Advancements in serum-based and imaging diagnostics improving disease detection accuracy.
  • Expanding pharma and CRO adoption supporting personalized liver disease treatment development.

• Leading Market Participants:

  Top companies in the non-alcoholic steatohepatitis biomarkers market include Siemens Healthineers AG (Germany), GENFIT S.A. (France), BioPredictive S.A. (France), Quest Diagnostics Incorporated (United States), Laboratory Corporation of America Holdings (United States), AstraZeneca PLC (United Kingdom), Pfizer Inc. (United States), Bristol-Myers Squibb Company (United States), Prometheus Laboratories Inc. (United States), Meridian Bioscience, Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 1.71 Billion
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 13.44 Billion by 2035
  • Growth Forecasts: 22.9% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Serum Biomarkers (Type) | Pharma & CRO Industry (End Use)
  • Emerging Opportunity Segment: Hepatic Fibrosis Biomarkers (Type) | Diagnostic Labs (End Use)

Market Growth Drivers and Industry Trends

Rising NASH prevalence driving demand for early non-invasive diagnostic biomarkers

As the number of patients with obesity, type 2 diabetes, and metabolic dysfunction rises, clinicians are seeing more individuals progress from simple fatty liver disease to suspected NASH, creating a larger screening and monitoring burden that liver biopsy cannot absorb efficiently. This is pushing the non-alcoholic steatohepatitis biomarkers market toward tools that can identify fibrosis risk and disease progression earlier through blood-based panels and other non-invasive approaches, especially in routine hepatology and endocrinology workflows where repeat assessment is necessary. The practical effect is stronger demand for biomarkers that help triage patients, reduce unnecessary invasive procedures, and support earlier referral decisions, driving demand for the market through broader use in at-risk populations.

Advancements in serum-based and imaging diagnostics improving disease detection accuracy

Improved sensitivity and specificity in serum biomarkers, algorithmic scoring models, and imaging-linked diagnostic approaches are making NASH assessment more clinically actionable, particularly where distinguishing steatosis from inflammatory injury and fibrosis stage has historically been difficult without biopsy. In the non-alcoholic steatohepatitis biomarkers market, this is influencing market adoption by increasing physician confidence in non-invasive testing for diagnosis, stratification, and longitudinal follow-up, while also encouraging healthcare providers to integrate multi-parameter diagnostic pathways into standard care. Better detection accuracy strengthens market development because test developers that can demonstrate clearer correlation with histological outcomes are more likely to gain traction in both clinical practice and therapeutic research settings.

Expanding pharma and CRO adoption supporting personalized liver disease treatment development

Drug developers and contract research organizations are using biomarker tools more intensively to enrich clinical trial populations, segment patients by fibrosis severity, and track biological response during NASH therapy development. That shift is strengthening the role of the non-alcoholic steatohepatitis biomarkers market beyond diagnosis alone, as biomarker platforms become embedded in trial design, companion stratification strategies, and endpoint evaluation for targeted liver disease programs. In practice, pharma and CRO adoption reinforces market demand for assays that are reproducible, scalable, and aligned with treatment-response assessment, because development programs increasingly depend on precise patient selection rather than broad enrollment in a heterogeneous disease population.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Growing prevalence of NASH and liver diseases	7.50%	Short term (≤ 2 yrs)	North America, Europe	Medium	Fast
Technological advancements in biomarker development	7.70%	Medium term (2–5 yrs)	North America, Asia Pacific	Low	Moderate
Expansion of clinical trials and research in emerging markets	7.70%	Long term (5+ yrs)	Asia Pacific, Latin America	Low	Slow
Rising NASH prevalence driving demand for early non-invasive diagnostic biomarkers	2.50%	High	North America, Europe	High	Near Term
Advancements in serum-based and imaging diagnostics improving disease detection accuracy	2.10%	High	North America, Asia Pacific	High	Mid Term
Expanding pharma and CRO adoption supporting personalized liver disease treatment development	1.80%	Moderate	North America, Europe	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 56.60% share of the non-alcoholic steatohepatitis biomarkers market in 2025, bolstered by its established diagnostic ecosystem, broad access to advanced laboratory testing, and strong integration of biomarker-based assessment into clinical research and specialist care pathways. The region’s lead is reinforced by active biomarker validation efforts, a concentrated base of biotechnology and diagnostic companies, and higher screening intensity among at-risk patient populations, which together sustain routine test utilization and research demand in real-world market activity.

Asia Pacific is projected to expand at a 25.19% CAGR over the forecast period, with growth in the non-alcoholic steatohepatitis biomarkers market accelerating as healthcare systems widen access to liver disease detection and clinical awareness improves across large patient populations. Adoption is being impelled by rising use of diagnostic testing in urban care settings, expanding research participation, and increasing focus on earlier identification of metabolic and liver-related conditions, creating stronger demand for biomarker tools in both clinical evaluation and development programs.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Developing
Cost-Sensitive Region	Low	High	Medium	High	High
Regulatory Environment	Restrictive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Strong	Strong	Moderate	Moderate
Development Stage	Developed	Developing	Developed	Developing	Emerging
Adoption Rate	High	High	High	Medium	Medium
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Strong	Stable	Stable	Stable

Key Country Insights

United States

Precision Diagnostic Adoption

The U.S. continues expanding non-alcoholic steatohepatitis biomarker adoption as healthcare providers seek non-invasive methods for liver disease assessment. Clinical research, pharmaceutical development, and diagnostic laboratories are accelerating biomarker validation and integration.

Japan

Early Detection Strategy

Japan is promoting non-alcoholic steatohepatitis biomarker development to strengthen early disease detection and reduce reliance on invasive procedures. Diagnostic innovation is closely linked with precision medicine and routine clinical practice.

South Korea

Translational Research Pipeline

South Korea is advancing non-alcoholic steatohepatitis biomarkers through collaborative research between biotechnology firms and healthcare institutions. Commercial priorities include improving assay performance and supporting patient stratification for clinical studies.

Germany

Clinical Validation Focus

Germany emphasizes clinically validated non-alcoholic steatohepatitis biomarkers to improve diagnostic confidence and patient management. Hospitals and research institutions are supporting standardized testing approaches alongside therapeutic development programs.

France

Integrated Liver Diagnostics

France is incorporating non-alcoholic steatohepatitis biomarkers into broader liver disease management strategies. Healthcare providers are evaluating non-invasive diagnostic tools that improve monitoring while supporting more personalized treatment decisions.

Italy

Diagnostic Pathway Enhancement

Italy is strengthening the use of non-alcoholic steatohepatitis biomarkers within hepatology services to improve diagnostic workflows. Growing collaboration between laboratories and clinicians supports wider evaluation of biomarker-based testing solutions.

Segment Leadership and Growth Trends

  Type Segment Analysis: Serum Biomarkers (Largest Segment) vs Hepatic Fibrosis Biomarkers (Fastest-Growing Segment)

Serum Biomarkers held a 33.07% share of the non-alcoholic steatohepatitis biomarkers market in 2025, reflecting their established role in routine testing workflows and broad usability across clinical and research settings. Their leadership is maintained through the practical advantage of blood-based assessment, which fits easily into repeat monitoring and large patient evaluations without adding procedural complexity. In the non-alcoholic steatohepatitis biomarkers market, this operational convenience supports continued reliance on Serum Biomarkers where scalable, accessible biomarker measurement is essential.

Hepatic Fibrosis Biomarkers are emerging as the fastest-growing type in the non-alcoholic steatohepatitis biomarkers market because fibrosis assessment is closely tied to disease progression and clinical decision-making. Growth is being reinforced through the increasing need for biomarker tools that help distinguish patients by severity and support more targeted evaluation pathways. Compared with broader biomarker categories, Hepatic Fibrosis Biomarkers are gaining stronger traction as market demand shifts toward more clinically actionable insights in non-alcoholic steatohepatitis management and study design.

End Use Segment Analysis: Pharma & CRO Industry (Largest Segment) vs Diagnostic Labs (Fastest-Growing Segment)

By 2025, the Pharma & CRO Industry accounted for the largest share of the non-alcoholic steatohepatitis biomarkers market, encouraged by its central role in biomarker validation, trial stratification, and therapeutic development activity. Leadership in this end-use segment is reinforced through the consistent need for biomarker applications across drug discovery and clinical research programs, where structured testing frameworks and repeated data collection are fundamental. In the non-alcoholic steatohepatitis biomarkers market, this keeps demand concentrated within Pharma & CRO Industry settings that depend on biomarker-supported development processes.

Diagnostic Labs represent the fastest-growing end-use segment in the non-alcoholic steatohepatitis biomarkers market as testing demand increasingly moves toward practical clinical evaluation environments. Their momentum comes from the need to process biomarker assessments in more routine and scalable settings, especially where patient identification and follow-up require efficient laboratory support. Relative to research-centered end users, Diagnostic Labs are gaining pace because they are better aligned with expanding real-world testing needs tied to non-alcoholic steatohepatitis biomarker adoption.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, Others	Serum Biomarkers	Hepatic Fibrosis Biomarkers
End Use	Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes	Pharma & CRO Industry	Diagnostic Labs

Competitive Landscape and Market Positioning

Leading companies in the non-alcoholic steatohepatitis biomarkers market:

1. Siemens Healthineers AG (Germany)

2. GENFIT S.A. (France)

3. BioPredictive S.A. (France)

4. Quest Diagnostics Incorporated (United States)

5. Laboratory Corporation of America Holdings (United States)

6. AstraZeneca PLC (United Kingdom)

7. Pfizer Inc. (United States)

8. Bristol-Myers Squibb Company (United States)

9. Prometheus Laboratories Inc. (United States)

10. Meridian Bioscience Inc. (United States)

The non-alcoholic steatohepatitis biomarkers market is advancing due to growing demand for early and accurate liver disease diagnostics. Continuous research is enabling discovery of more precise biomarker panels for improved clinical assessment. Collaborative development efforts are enhancing diagnostic tool integration, while new testing solutions are improving accessibility and accuracy. These developments are strengthening innovation in the biomarkers market.

Industry Development/News

Company Name	Date	Key Development
SomaLogic	Jul-24	SomaLogic introduced new protein biomarkers for Non-alcoholic Steatohepatitis (NASH), providing mechanistic and clinical insights into acetyl-CoA carboxylase (ACC). The development strengthens non-invasive diagnostic capabilities by advancing biomarker-based approaches for disease identification and progression assessment in liver disease management.
Gilead Sciences	Feb-24	Gilead Sciences completed a USD 4.3 billion acquisition of CymaBay Therapeutics to expand its liver disease portfolio, including Seladelpar, a PPARδ agonist for primary biliary cholangitis. The transaction enhances Gilead’s positioning in hepatology-focused therapeutics relevant to NASH-related disease pathways.
GENFIT	Sep-20	GENFIT signed a five-year exclusive licensing agreement with LabCorp for commercialization of its NIS4 blood-based molecular diagnostic technology for identifying NASH patients at risk of disease progression. The collaboration expands access to non-invasive biomarker-based testing across the U.S. and Canada.